QUANTUM X LABS INC. annual report, FY2016

Business context and reporting period

Filing identity: The supplied request names QUANTUM X LABS INC., but the filing is for Emerald Medical Applications Corp. (OTCQB: MRLA). Confirm the intended issuer before relying on this summary. This is the company’s annual report for the fiscal year ended December 31, 2016, not a standalone fourth-quarter report.

Emerald is an early-stage digital-health company developing and marketing DermaCompare, software intended to analyze total-body and lesion images to help monitor skin changes. The company reported no revenue in either 2016 or 2015 and described its marketing efforts as early-stage.

Financial results and liquidity

MetricFY 2016FY 2015
Revenue$0$0
Research and development$1,644,868$740,197
General and administrative expenses$3,749,867$7,303,292
Operating loss$5,394,735$8,043,489
Net loss$5,808,925$8,756,267
Basic and diluted loss per share$0.31$0.81
Net cash used in operating activities$858,533$1,301,823

Gross margin is not meaningful because the company reported no revenue. The net loss narrowed year over year, while R&D expense increased; 2015 included a $678,027 loss on debt settlement and higher G&A. FY 2016 results included substantial non-cash compensation and debt-discount amortization.

At December 31, 2016, audited statements report cash of $4,486, current assets of $13,842, total assets of $57,570, and current liabilities of $958,197. Negative working capital was $944,355, versus $147,529 a year earlier. Current liabilities included a $409,588 convertible note, net of discount, and other payables. Stockholders’ deficit was $900,627. Financing cash flows were $782,600, comprising $47,600 net proceeds from stock and warrants and $735,000 from convertible notes.

Material changes versus the prior year

  • Net loss declined by about $2.9 million, mainly as 2015 G&A and debt-settlement charges were higher; R&D expense more than doubled.
  • Operating cash use improved from $1.30 million to $858,533, but cash fell from $115,449 to $4,486.
  • Current liabilities rose to $958,197 from $288,775, and negative working capital worsened substantially.
  • Common shares outstanding increased during the year; the filing also reports significant options and warrants that could further dilute shareholders.

Outlook, risks, contingencies and unusual items

Management said it may need up to $1.5 million in additional capital over the next 12 months to execute its plan and fund operations. The auditor’s report and management disclosures state that the lack of revenue, losses, limited cash and dependence on additional financing raise substantial doubt about the company’s ability to continue as a going concern. The financial statements contain no adjustments for a possible failure to continue as a going concern.

Management reported ineffective disclosure controls and material weaknesses in internal control over financial reporting, citing insufficient accounting personnel to document complex transactions and support adequate reporting. Management planned corrective action beginning in the second quarter of 2017; the auditor did not attest to internal-control effectiveness.

Key business risks include failure to raise capital, lack of physician or patient adoption, competition, product defects, data-security incidents, regulatory and reimbursement changes, intellectual-property challenges, and dependence on key personnel. The CEO had notified the board she would leave effective June 23, 2017. Subsequent to year-end, former CEO Lior Wayn transferred shares and 900,000 Class E warrants to an entity controlled by director Alimi Ahmed; the filing also reports cancellation of remaining Class E warrants.

Other notable disclosures: the company said its software was FDA Class I; it completed PCT registration of two patent applications in 2016. Israeli research grants of approximately $222,000 carry royalties of 3.5% of sales, capped at the grant amount, payable only if qualifying sales occur. The company reported no ongoing litigation. A Publicis competition award of €500,000 (approximately $526,000) was described; the related share issuance occurred in 2017 and is a subsequent event, not 2016 revenue.

Most important facts to verify

  • Issuer and period: Confirm that Emerald Medical Applications Corp. and FY 2016 are the intended subject; the request metadata identifies a different company and “2016 Q4.”
  • Reported amounts: The filing contains conflicting figures. MD&A states operating cash use of $818,533, while the cash-flow statement reports $858,533. MD&A lists accounts payable and accrued liabilities of $258,795 and employee payable of $101,341; the balance sheet lists $198,795 and $161,341, respectively.
  • Capital raised and share count: Disclosures cite $948,978 and $989,974 raised during 2016, while the cash-flow statement reports $782,600 of financing cash inflows. The cover reports 19,962,728 year-end shares, while the balance sheet reports 19,931,478.
  • Funding runway and debt terms: Review the convertible-note agreements, maturities, conversion provisions, security and any financing completed after year-end; year-end cash was only $4,486 and management anticipated needing up to $1.5 million.
  • Dilution and governance: Reconcile outstanding options, warrants and share counts, and review the control weaknesses, planned remediation, and CEO transition.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.